Competition

Five things for pharma marketers to know: Tuesday, September 6, 2016

Five things for pharma marketers to know: Tuesday, September 6, 2016

By

MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug

Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

By

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

By

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

By

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Five things for pharma marketers to know: Friday, June 3, 2016

Five things for pharma marketers to know: Friday, June 3, 2016

By

Generic drugmakers consider pricing strategies; Mary Meeker predicts images and search will be half of online searches; drugmakers use comics to market

Five things for pharma marketers to know: Monday, February 1, 2016

Five things for pharma marketers to know: Monday, February 1, 2016

By

AbbVie cuts 2016 sales estimate for Viekira Pak; Abbott to acquire Alere for $5.8 billion; Express Scripts to stop covering Valeant's Glumetza

Five things for pharma marketers to know: Tuesday, December 8, 2015

Five things for pharma marketers to know: Tuesday, December 8, 2015

By

Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma

OPINION

Email Newsletters